Who Generates Higher Gross Profit? Pfizer Inc. or Halozyme Therapeutics, Inc.

A Tale of Two Giants: Pfizer Inc. vs. Halozyme Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, the battle for supremacy often boils down to financial prowess. Over the past decade, Pfizer Inc. has consistently outperformed Halozyme Therapeutics, Inc. in terms of gross profit. From 2014 to 2023, Pfizer's gross profit averaged around $42 billion annually, dwarfing Halozyme's $259 million. Notably, Pfizer's peak in 2022 saw a staggering $66 billion, while Halozyme's highest was $637 million in 2023. Despite Halozyme's impressive growth, increasing its gross profit by over 1,100% from 2014 to 2023, it remains a David to Pfizer's Goliath. This financial narrative underscores the scale and impact of Pfizer's operations, driven by its expansive product portfolio and global reach. As the industry continues to innovate, the question remains: can Halozyme close the gap, or will Pfizer maintain its dominant position?